NCT04571229

Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma

• Status: Available
• Phase: —
• Study type: Expanded Access
• Enrollment: —
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: —

Summary

This expanded access protocol will allow access to treatment with L-MTP-PE for people with osteosarcoma. L-MTP-PE is an investigational drug that has not been approved by the FDA to treat any condition, including osteosarcoma. L-MTP-PE works by activating certain types of white blood cells, and these active white blood cells help the immune system kill cancer cells.

Conditions

• Osteosarcoma

Interventions

Type	Name	Description
DRUG	L-MTP-PE	L-MTP-PE will be administered at a dose of 2mg/m2 (maximum dose 4 mg), twice weekly for 12 weeks and weekly for an additional 24 weeks, for a total of 48 doses in 36 weeks.

Timeline

• First posted: 2020-09-30
• Last updated: 2026-03-18

Locations

1 site across 1 country: United States